Celsion Corp., a biotechnology drug development company in Columbia, Maryland, has received a Phase 1 Small Business Innovation and Research (SBIR) grant from the National Institutes of Health. This funding will help the company develop its heat-activated liposomal — encapsulated cellular membrane sac — technology in combination with carboplatin, a frequently used oncology drug for treatment of a wide range of cancers.
The grant is valued at approximately $200,000 and will support formulation development and preclinical efficacy studies with Duke University. Phase 1 SBIR grants fund feasibility and proof-of-concept studies.
Celsion develops cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion’s lead product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, a cancer chemotherapy drug. ThermoDox is currently in a phase 3 clinical trial for the treatment of liver cancer (hepatocellular carcinoma) and in a Phase 1/2 trial for patients with recurrent chest wall breast cancer.
RSS - Posts